Oncomedicine 2017; 2:102-110. doi:10.7150/oncm.18405

Research Paper

In vitro single-strand DNA damage and cancer cell cytotoxicity effects of Temozolomide

Shruti Purohit*, Devashree Jahagirdar*, Azad Kumar, Nilesh Kumar Sharma

Dr. D. Y Patil Biotechnology & Bioinformatics Institute, Dr. D.Y. Patil Vidyapeeth, Pune, Maharashtra, India-411033.
* Both are co-first author

Abstract

Temozolomide (TMZ) is approved against certain tumors, but substantial evidences are scarce to demonstrate TMZ as single-strand DNA break agent and reasons behind lack of responses in carcinoma. Plasmid and genomic DNA included as a substrate during assessment of in vitro single-strand break potential of TMZ. Cell based assay was performed to assess DNA damaging activity and cytotoxicity in HeLa. Further, authors tried to evaluate DNA damage and overall cytotoxicity in HeLa using Trypan blue dye exclusion and apoptotic DNA fragmentation assays. Data indicate that TMZ can generate extensive single-strand break on different DNA substrate. A DNA ligase inhibitor L189 appears to plays synergistic role in TMZ ability to decrease cell proliferation in HeLa and some extent of cytotoxicity. However, authors noticed none apoptotic DNA fragments due to toxicity effects of TMZ alone or combined TMZ plus L189. Based on our observations, findings support combined use of TMZ and L189 inhibitor to enhance responsiveness in HeLa possibly by decreasing cellular growth instead of apoptotic cell death pathway.

Keywords: Nicking, Genotoxic drugs, Cancer, Supercoiling, DNA relaxation, Temozolomide.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Purohit S, Jahagirdar D, Kumar A, Sharma NK. In vitro single-strand DNA damage and cancer cell cytotoxicity effects of Temozolomide. Oncomedicine 2017; 2:102-110. doi:10.7150/oncm.18405. Available from http://www.oncm.org/v02p0102.htm